World Immune-checkpoint Drugs in Oncology Analytical Handbook 2022
June 08, 2022 03:18 ET
|
Research and Markets
Dublin, June 08, 2022 (GLOBE NEWSWIRE) -- The "Immune-checkpoint Drugs in Oncology: Analytical Tool" report has been added to ResearchAndMarkets.com's offering. Immune-checkpoint Drugs in Oncology:...
Immuno-Oncology Drug Development Analytical Tool 2022: 1260 Companies/Partners Who are Developing 3,896 I-O Drugs Where of 2,948 are in Active Development in Cancer Across 629 Different Targets
May 26, 2022 06:28 ET
|
Research and Markets
Dublin, May 26, 2022 (GLOBE NEWSWIRE) -- The "Immuno-Oncology Drug Development: Analytical Tool" report has been added to ResearchAndMarkets.com's offering. Immuno-Oncology Drug Development:...
2022 Oncolytic Virotherapies Analytical Tool: 85 Companies Who are Developing 150 Oncolytic Virus Drugs Where 113 are in Active Development in Cancer Across 40 Different Targets
May 11, 2022 07:03 ET
|
Research and Markets
Dublin, May 11, 2022 (GLOBE NEWSWIRE) -- The "Oncolytic Virotherapies: Analytical Tool" report has been added to ResearchAndMarkets.com's offering.Oncolytic Virotherapies: Analytical Tool is the...
Global $140+ Billion Immune Checkpoint Inhibitors Market Opportunity Analysis and Industry Forecasts to 2030
March 29, 2022 05:38 ET
|
Research and Markets
Dublin, March 29, 2022 (GLOBE NEWSWIRE) -- The "Immune Checkpoint Inhibitors Market by Type and Application: Global Opportunity Analysis and Industry Forecast, 2021-2030" report has been added to...
Global Immune Checkpoint Inhibitors $30 Billion Market Opportunity
March 15, 2022 05:53 ET
|
Research and Markets
Dublin, March 15, 2022 (GLOBE NEWSWIRE) -- The "Global Immune Checkpoint Inhibitors Biomarkers & Clinical Trials Insight 2028" drug pipelines has been added to ResearchAndMarkets.com's...
Immune Checkpoint Inhibitors Market is Expected to Reach $140.89 Billion by 2030: Says AMR
February 17, 2022 10:07 ET
|
Allied Market Research
Portland, OR, Feb. 17, 2022 (GLOBE NEWSWIRE) -- According to the report published by Allied Market Research, the global immune checkpoint inhibitors market was estimated at $29.80 billion in 2020...
CD47 Targeting Global Therapeutics Market 2021-2035, by Target Disease Indication, Type of Molecule Key Players and Key Geographical Regions
December 15, 2021 04:03 ET
|
Research and Markets
Dublin, Dec. 15, 2021 (GLOBE NEWSWIRE) -- The "CD47 Targeting Therapeutics Market Industry Trends and Global Forecasts, 2021-2035" report has been added to ResearchAndMarkets.com's offering. ...
Global Checkpoint Inhibitors Market (2021 to 2030) - Featuring AstraZeneca, Roche Holding and Pfizer Among Others
December 07, 2021 06:58 ET
|
Research and Markets
Dublin, Dec. 07, 2021 (GLOBE NEWSWIRE) -- The "Checkpoint Inhibitors Global Market Report 2021: COVID-19 Growth and Change to 2030" report has been added to ResearchAndMarkets.com's offering. This...
Cancer Advances, Inc. Announces Publication, "Gastrin Vaccine Alone and in Combination with an Immune Checkpoint Antibody Inhibits Growth and Metastases of Gastric Cancer" in Frontiers in Oncology
December 06, 2021 10:00 ET
|
Cancer Advances Inc
DURHAM, N.C., Dec. 06, 2021 (GLOBE NEWSWIRE) -- Cancer Advances, Inc., a clinical stage biopharmaceutical company developing therapeutics for gastrointestinal cancers, announces a new publication in...
ImCheck Publishes Comprehensive Overview of the Development Results of Its First-in-class Cancer Immunotherapeutic Targeting BTN3A to Activate Vγ9Vδ2 T Cells in Science Translational Medicine
October 20, 2021 14:21 ET
|
ImCheck Therapeutics SAS
ImCheck Publishes Comprehensive Overview of the DevelopmentResults of Its First-in-class Cancer Immunotherapeutic Targeting BTN3A to Activate Vγ9Vδ2 T Cellsin Science Translational Medicine ...